Investors

GlobeImmune received $5 million in seed and grant financing from a variety of sources prior to completing an $8 million Series A financing with Sequel Venture Partners of Boulder, CO; HealthCare Ventures, LLC. of Cambridge, MA; and Morgenthaler Ventures of Menlo Park, CA in 2003.

In December 2005, GlobeImmune closed $38.4 million in Series B financing to support continued clinical development of its lead programs. This round was led by Lilly Ventures and included other new investors Medica Venture Partner, Adams Street Partners, PAC-LINK Bio, CIDC, Biogen Idec, Inc., Genentech, Inc., Yasuda, Partners Healthcare and GC&H Investments. All of the Company’s original Series A Preferred Stock investors also participated in the financing.

In September 2007, GlobeImmune closed a $41.2 million Series C financing led by Wexford Capital LLC.  Other new investors in GlobeImmune included Celgene, Inc., Mellon Family Investment Company, Eminent Venture Capital, Boston Life Science Venture, and WRF Capital. 

In May 2009, the Company signed a broad oncology partnership with the Celgene Corporation.  Under the terms of the agreement, GlobeImmune received a $40 million upfront payment from Celgene, which includes a $10 million Series D equity investment in the Company.

In January 2010, announced a Series E Preferred Stock financing of $18 million. The round was led by new investors Generali Financial Holding.  Advisory for the new investors was BSI Healthcapital SA of Lugano, Switzerland. Existing investors in GlobeImmune also participated in the financing.

If you would like to receive our press releases directly, please submit your name and email address.  Go to press release sign-up page.